MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical
company bringing innovative therapies to address unmet needs in
severe burn and wound management, announces that the Board of
Directors has appointed Vickie R. Driver, DPM and Stephen T. Wills,
CPA to its Board of Directors, effective immediately. In addition,
the Board recommends that shareholders elect Nissim Mashiach and
Sharon Kochan as external directors at the upcoming shareholder
meeting scheduled for June 22, 2017, as the terms of the following
directors will expire in June: Sarit Firon, Avri Havron, Ph.D.,
Marian Gorecki, Ph.D. and Meron Mann.
“We believe that reconstituting the Board with
seasoned executives in the U.S. wound care industry will
considerably contribute to our strategy of maximizing the potential
value of NexoBrid® and EscharEx®," stated Aharon Yaari, Chairman of
the Board of MediWound. "These executives possess strong science
and business backgrounds, and add decades of drug development,
global business development/partnering and U.S. product
commercialization capabilities. These attributes, will be
invaluable as we accelerate and enhance the value of MediWound’s
core assets under development and assess additional strategic
avenues to create the greatest value for our shareholders. On
behalf of the Board of Directors, I thank Ms. Firon, Dr. Havron,
Prof. Gorecki and Mr. Mann for their years of contribution and
service to MediWound,” concluded Mr. Yaari.
About Vickie R. Driver, DPM, MS,
FACFAS
Dr. Driver is board certified in foot surgery by
the American Board of Podiatric Surgery and is a Fellow at the
American College of Foot and Ankle Surgeons, licensed in Rhode
Island. Her career as a podiatric physician and surgeon has
included a special emphasis on limb preservation and wound healing
in her medical practice, as well as, research and education. Dr.
Driver is a Professor of Surgery in the Department of Orthopedics
at Brown University (Clinical). She has served for 9 years on the
Board of Directors for the Association for the Advancement of Wound
Care ("AAWC"), and recently completed her tenure as president for
this international organization. Dr. Driver is also the chair of
Wound Care Experts and U.S. Food and Drug Administration (FDA)
Clinical Endpoints Project. She has just been named to serve
as member at large to the Board of Directors of the Wound Healing
Society (WHS) and Board Member to the Critical Limb Ischemia (CLI)
Global Society. In addition, she serves on multiple clinical
national and international committees that focus on preventing limb
loss and improving wound healing in the high-risk population. She
is considered an outspoken ambassador and patient advocate for
lower extremity limb preservation and amputation prevention. She
has served as an investigator for more than 70 important
multi-center randomized clinical trials, as well as developed and
supervised multiple research fellowship training programs. She has
served and chaired multiple committees for large national and
international pivotal clinical trials and has authored over 120
publications and abstracts. Dr. Driver is credited with the
development and directorship of multiple major multidisciplinary
Limb Preservation- Wound Healing Centers of Excellence, including
Military/VA, Hospital and University based programs. She currently
serves as Director, Translational Medicine, Wound Healing, Novartis
Institute for Biomedical Research.
About Stephen T. Wills, CPA
Mr. Wills, has served, since 1997, as Executive
Vice President, Secretary, Treasurer and Chief Financial Officer of
Palatin Technologies, Inc., a publicly-held biopharmaceutical
company developing targeted, receptor-specific peptide therapeutics
for the treatment of diseases with significant unmet medical need
and commercial potential. He has served in various roles in
Palatin since 1997, including as Executive Vice President of
Operations from 2005 until June 2011 and as Chief Operating Officer
and Executive Vice President from 2011 to present. Mr. Wills served
as Executive Chairman and Interim Principal Executive Officer of
Derma Sciences, Inc., a publicly-held company providing advanced
wound care products, from December 2015 until February 2017 when
Derma was acquired by Integra LifeSciences Holding Corporation. Mr.
Wills also served as the lead director of Derma Sciences until
December 2015 and as Derma Science’s Chief Financial Officer from
1997 to 2000. Mr. Wills serves on the board of trustees and
executive committee of The Hun School of Princeton, and from 1991
to 2000 he was the President and Chief Operating Officer of Golomb,
Wills & Company, P.C., a public accounting firm. Mr. Wills, a
certified public accountant, received his B.S. in accounting from
West Chester University, and an M.S. in taxation from Temple
University.
About Nissim Mashiach
Mr. Mashiach served as President and Chief
Executive Officer of Macrocure Ltd. from June 2012 to January
2017. Macrocure was a Nasdaq listed biotechnology company
focused on developing, manufacturing and commercializing novel cell
therapy products to address unmet needs in the treatment of chronic
and other hard-to-heal wounds. From 2009 to 2012, he served as
General Manager at Ethicon, a Johnson & Johnson company. Prior
to Ethicon, he served as President and Chief Operating Officer at
Omrix Biopharmaceuticals, Inc., a company acquired by Johnson &
Johnson in 2008. Prior to Omrix, Mr. Mashiach held leadership
positions at several pharmaceutical companies. He holds an MBA from
the University of Manchester (Manchester, England), an MPharmSc
from the Hebrew University (Jerusalem, Israel), and a B.Sc,
Chemical Engineering from the Technion-Israel Institute of
Technology (Haifa, Israel).
About Sharon Kochan
Mr. Kochan has served as Executive Vice
President & President, International, for Perrigo Company Plc.
since 2012, and is a member of Perrigo Executive Committee since
2007. Perrigo Company plc. is a global, multibillion,
over-the-counter, consumer goods and specialty pharmaceutical
company listed on the New York Stock Exchange. From March 2007 to
July 2012, he served as Executive Vice President, General Manager
of Prescription Pharmaceuticals for Perrigo and from 2005 to 2007,
he was Senior Vice President of Business Development and Strategy
for Perrigo. Mr. Kochan was Vice President, Business Development of
Agis Industries (1983) Ltd. from 2001 until Perrigo acquired Agis
in 2005. He completed the Senior Management Program at the
Technion Institute of Management (Haifa, Israel), received a Master
of Science in Operations Research & Management Science from
Columbia University (New York City) and received a Bachelor of
Science in Industrial and Management Engineering from Tel-Aviv
University (Tel-Aviv, Israel).
About MediWound Ltd.
MediWound is a fully-integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented
proteolytic enzyme technology to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds. MediWound’s
first innovative biopharmaceutical product, NexoBrid®, received
marketing authorization from the European Medicines Agency as well
as the Israeli and Argentinian Ministries of Health, for removal of
dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in Europe
and Israel, with plans for a launch in Argentina.
NexoBrid® represents a new paradigm in burn care management,
and clinical trials have demonstrated, with statistical
significance, its ability to non-surgically and rapidly remove the
eschar earlier and, without harming viable tissues.
MediWound's second innovative product, EscharEx®
is a topical biological drug being developed for debridement of
chronic and other hard-to-heal wounds and is complementary to the
large number of existing wound healing products, which require a
clean wound bed in order to heal the wound. EscharEx® contains the
same proteolytic enzyme technology as NexoBrid®, and benefits from
the wealth of existing development data on NexoBrid®. In two
Phase 2 studies, EscharEx® has demonstrated safety and efficacy in
the debridement of chronic and other hard-to-heal wounds, within a
few daily applications. For more information, please
visit www.mediwound.com.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes
forward-looking statements within the meaning of Section 27A of the
U.S. Securities Act of 1933, as amended, Section 21E of the US
Securities Exchange Act of 1934, as amended, and the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are statements that are not
historical facts, such as statements regarding assumptions and
results related to the regulatory authorizations and launch
dates. In some cases, you can identify forward-looking
statements by terminology such as “believe,” “may,” “estimate,”
“continue,” “anticipate,” “intend,” “should,” “plan,” “expect,”
“predict,” “potential,” or the negative of these terms or other
similar expressions. Forward-looking statements are based on
MediWound’s current knowledge and its present beliefs and
expectations regarding possible future events and are subject to
risks, uncertainties and assumptions. Actual results and the timing
of events could differ materially from those anticipated in these
forward-looking statements as a result of several factors. In
particular, you should consider the risks discussed under the
heading “Risk Factors” in our annual report on Form 20-F for the
year ended December 31, 2016 and information contained in other
documents filed with or furnished to the Securities and Exchange
Commission. You should not rely upon forward-looking statements as
predictions of future events. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or will occur. The
forward-looking statements made herein speak only as of the date of
this announcement and MediWound undertakes no obligation to update
publicly such forward-looking statements to reflect subsequent
events or circumstances, except as otherwise required by law.
Contacts:
Sharon Malka
Chief Financial and Operations Officer
MediWound
ir@mediwound.co.il
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Apr 2023 to Apr 2024